This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Grocery Outlet, Sprouts Farmers, PLDT, Regeneron and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Grocery Outlet, Sprouts Farmers, PLDT, Regeneron and Clorox
S&P Sees Worst-Ever Q1: 5 Stocks That Gained in the ETF
by Sweta Killa
Though all 11 sectors in the S&P 500 index were down in the quarter, information technology and healthcare fared better than others.
Top Stock Trades to Beat Coronavirus Blues in April
by Tirthankar Chakraborty
The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.
6 Top S&P 500 Stocks That Have Surged Despite Worst-Ever Q1
by Nalak Das
The disappointing performance in Q1 is not due to any economic, financial or geopolitical factors but instead a health hazard ??? the coronavirus pandemic.
Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
by Zacks Equity Research
Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.
Gilead Expands Access to Experimental Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.
6 Defensive Stocks Worth Buying as Coronavirus Cases Rise
by Zacks Equity Research
The current economic slowdown led by rise in coronavirus cases calls for investing in defensive stocks.
Company News for Mar 31, 2020
by Zacks Equity Research
Companies In The News Are: SPCB, OMI, CVU, REGN
5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil
by Nalak Das
A handful of stocks have withstood the market mayhem in March, some of them are momentum players.
Sanofi Begins Kevzara Study for Severe Coronavirus Infection
by Zacks Equity Research
Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for EUSA
3 Best U.S. Stocks Immune to Coronavirus Jitters
by Manaswita Ghosh Dutta
The pandemic may be taking a toll on markets right now but this temporary phase offers investors a window to buy equities that have a record of performing better than the broader markets.
Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir
by Zacks Equity Research
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
by Zacks Equity Research
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
When Do U.S. Stocks Get a Green Light?
by John Blank
Short answer - Not clear. Buy on yellow.
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
US Government Reaches Deal on Stimulus Package: 5 Top Picks
by Nalak Das
The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $449.53, marking a -1.34% move from the previous day.
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
Roche Gets FDA Approval for Actemra Trials in COVID-19
by Zacks Equity Research
Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands